Date: 2014-04-22
Type of information: Distribution agreement
Compound: ConfirmMDx® for Prostate Cancer
Company: MDxHealth (Belgium) Galaxy Health Network (USA -TX)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement:
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or \"halo\" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular \"halo\" around a cancer lesion can be present despite having a normal appearance under the microscope.
Disease: prostate cancer
Details: * On April 22, 2014, MDxHealth SA, a Belgian molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, has announced that it has signed an agreement with Galaxy Health Network, a Preferred Provider Organization (PPO). The agreement provides patients nationwide with greater access to MDxHealth\'s ConfirmMDx® for Prostate Cancer test. This agreement extends ConfirmMDx for Prostate Cancer testing to approximately 147 million covered lives throughout the U.S.The agreement further expands MDxHealth\'s payor base, improving claims adjudication times and facilitating reimbursement for the ConfirmMDx for Prostate Cancer test. MDxHealth continues to increase coverage and access to its test for patients at in-network benefit levels across the U.S. contracting with PPO, Third Party and other Payer networks. Galaxy Health Network, based in Arlington, TX, has a provider base to over 400,000 physicians, 2,700 hospitals and 47,000 ancillary providers - all directly contracted. Its member base has currently more than 3.5 million covered lives.
Financial terms:
Latest news:
